Travers Smith advised Care REIT Plc on the deal. Care REIT Plc, a UK-based real estate investment fund specializing in care homes, has accepted a £488...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Light Horse Therapeutics on the transaction. Light Horse Therapeutics, a developer of small molecule therapeutics, announced its multi-target collaboration with...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Cimeio Therapeutics on the transaction. Cimeio Therapeutics, an immunotherapy company, announced that it has entered a research collaboration with Kyowa...
You must be a Standard 1 Year member to access this content.
Ropes & Gray represented AvenCell Therapeutics in the transaction, and Wilson Sonsini Goodrich & Rosati advised Novo Holdings and F-Prime Capital on the transaction. AvenCell Therapeutics...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Borealis Biosciences on the transaction. Borealis Biosciences (Borealis), a next-generation RNA medicines company, emerged from stealth with $150 million in...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Fluent Biosciences on the transaction. Illumina, Inc. (NASDAQ: ILMN) announced it has acquired Fluent BioSciences (Fluent), developer of an emerging...
You must be a Standard 1 Year member to access this content.
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian advised Radar Therapeutics on the deal, and Wilson Sonsini Goodrich & Rosati advised Radar Therapeutics on IP matters related...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised SR One, Norwest Venture Partners, and Delos Capital on the transaction. Zenas BioPharma, a clinical-stage global biopharmaceutical company, announced an...
You must be a Standard 1 Year member to access this content.
King & Spalding has secured USD $900 million dollars for Reficar in its long running dispute with CB&I. The dispute with CB&I, owned by McDermott International since...
You must be a Standard 1 Year member to access this content.
King & Spalding has secured USD $900 million dollars for Reficar in its long running dispute with CB&I. The dispute with CB&I, owned by McDermott International since...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati represented Tempo Therapeutics in the transaction. Tempo Therapeutics, Inc. (“Tempo”) announced the completion of a $12 million Series A equity financing round, led by...
You must be a Standard 1 Year member to access this content.
King & Spalding assisted Électricité de France and Masdar on the concession agreement. EDF (Électricité de France), French multinational electric utility company, and Masdar, leading clean...
You must be a Standard 1 Year member to access this content.
